
zzso is a primary risk factor for multiple zzso zzso Many drugs for the treatment of zzso which mainly act through zzso as appetite zzso have failed during development or been removed from the market due to unacceptable adverse zzso Thus, there are very few zzso drugs available and remains a great zzso medical need for zzso drugs that increase energy expenditure by acting on peripheral zzso without severe side zzso Here, we report a novel approach involving zzso zzso of zzso growth factor zzso 4 zzso in peripheral zzso Treatment of zzso obese zzso mice with zzso zzso zzso zzso specifically reduced liver zzso expression that not only resulted in decrease in body weight zzso and zzso in zzso conditions, but also lowered zzso and zzso under caloric zzso In addition, combination treatment with zzso zzso and zzso showed additive reduction in zzso and zzso zzso zzso treatment increased zzso zzso rate during zzso conditions and, more importantly, prevented zzso decreases of zzso rate induced by caloric zzso The treatment increased fatty acid zzso while decreased zzso in both liver and zzso zzso studies indicated that zzso effect of zzso zzso was zzso at least in part through an induction of plasma zzso level resulted from reduction of zzso zzso zzso The zzso effect was accompanied by improvement in plasma zzso whole body insulin sensitivity, plasma zzso levels and liver zzso zzso zzso could be a potential novel target and zzso reduction of zzso zzso expression could be an zzso therapy as an adjunct to diet restriction or to an appetite zzso for the treatment of obesity and related zzso zzso 

